Palmerini, E, Pousa, AL, Grignani, G, Redondo, A, Hindi, N, Provenzano, S, Sebio, A, Martin, JAL, Valverde, C, Trufero, JM, Gutierrez, A, de Alava, E, Gomez, MPA, D'Ambrosio, L, Collini, P, Bazzocchi, A, Moura, DS, Ibrahim, T, Stacchiotti, S, Broto, JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2025; 131(1)DOI:10.1002/cncr.35628. PMID:39540661. IF:5.100(Q1/3D).

Salazar, J, Arranz, MJ, Martin-Broto, J, Bautista, F, Martínez-García, J, Martínez-Trufero, J, Vidal-Insua, Y, Echebarria-Barona, A, Díaz-Beveridge, R, Valverde, C, Luna, P, Vaz-Salgado, MA, Blay, P, Alvarez, R, Sebio, A. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024; 16(12)DOI:10.3390/pharmaceutics16121585. PMID:39771563. IF:5.500(Q1/1D).

Caballero-Borrego, M, Piedra, A, Gallego, O, López-Pousa, A, Castillo, P, Navarrete, P, Prat, A, Grau, JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology. 2024; 90(6)DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1.800(Q2/4D).

Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).